PMID- 3403092
OWN - NLM
STAT- MEDLINE
DCOM- 19880920
LR  - 20131121
IS  - 0174-4879 (Print)
IS  - 0174-4879 (Linking)
VI  - 26
IP  - 1
DP  - 1988 Jan
TI  - Pharmacokinetics of pengitoxin and its therapeutic efficacy in congestive heart 
      failure.
PG  - 8-15
AB  - In a therapeutic study, 120 inpatients suffering from congestive heart failure 
      were treated with a daily maintenance dose of 0.3 mg pengitoxin 
      (penta-acetyl-gitoxin) over several weeks or months. The plasma level and the 
      glycoside concentration in urine were measured by radioimmunoassay. The 
      therapeutic effects were evaluated considering clinical signs and criteria 
      following the functional capacity according to the New York Heart Association 
      (NYHA). In 27 patients both plasma and urine concentration were measured during 2 
      weeks after the beginning of the pengitoxin therapy. On the 3rd day of the 
      pengitoxin dosage schedule, a mean plasma level of 18.1 ng.ml-1 (SD 5.1 ng.ml-1) 
      was measured. During this day 26.6% of the daily administered glycoside dose was 
      excreted in urine. In 26 of the 120 patients the mean steady state plasma level 
      was between 7.6 and 22.5 ng.ml-1. A maximum of frequency was found in the 17.6 to 
      22.5 ng-subclass. In 118 patients the mean urinary excretion of 16-acetyl-gitoxin 
      reached 24.7% (SD 11.8%) of the administered dose. The creatinine clearance and 
      the 16-acetyl-gitoxin plasma level did not correlate, while between the renal 
      clearance values of creatinine and the glycoside a correlation was found, 
      however, it was of no significance for dosage schedules in patients with impaired 
      renal function. After treatment, the NYHA classes III and II were reached in 57 
      patients; in 3 patients suffering from renal diseases, the NYHA class I remained 
      unchanged. In 90 patients the clinical signs improved and in 27 patients the 
      clinical situation remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Haustein, K O
AU  - Haustein KO
AD  - Institute of Clinical Pharmacology, Medical Academy Erfurt, GDR.
FAU - Wesser, M
AU  - Wesser M
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther Toxicol
JT  - International journal of clinical pharmacology, therapy, and toxicology
JID - 8003415
RN  - 0 (Acetyldigoxins)
RN  - 0 (Glycosides)
RN  - 15RPL803R9 (pentaacetylgitoxin)
RN  - 73K4184T59 (Digoxin)
SB  - IM
MH  - Acetyldigoxins/administration & dosage/*pharmacokinetics/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biological Availability
MH  - Digoxin/*analogs & derivatives
MH  - Electrocardiography
MH  - Female
MH  - Glycosides/blood
MH  - Heart Failure/complications/*drug therapy/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 1988/01/01 00:00
MHDA- 1988/01/01 00:01
CRDT- 1988/01/01 00:00
PHST- 1988/01/01 00:00 [pubmed]
PHST- 1988/01/01 00:01 [medline]
PHST- 1988/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Ther Toxicol. 1988 Jan;26(1):8-15.